Minerva Neurosciences (NERV) Equity Average (2014 - 2026)

Minerva Neurosciences has reported Equity Average for 13 years, with the latest figure at -$197.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 619.82% year-over-year to -$197.4 million; the trailing twelve-month figure through Mar 2026 stood at -$197.4 million (down 619.82% YoY), and the FY2025 full-year result was -$83.2 million, down 207.37% from the prior year.
• Equity Average for Q1 2026 stood at -$197.4 million, down from -$87.7 million in the prior quarter.
• The five-year high for Equity Average was $3.6 million in Q1 2022, with the low at -$197.4 million in Q1 2026.
• Historically, Equity Average has averaged -$36.4 million across 5 years, with a median of -$24.3 million in 2023.
• Annual changes were most pronounced in 2023 — Equity Average sank 744.28% — and 2025, when it grew 24.45%.
• Minerva Neurosciences' Equity Average stood at -$17.1 million in 2022, then slumped by 41.53% to -$24.3 million in 2023, then rose by 2.35% to -$23.7 million in 2024, then plunged by 270.17% to -$87.7 million in 2025, then plunged by 125.16% to -$197.4 million in 2026.
• The last three Equity Average figures came in at -$197.4 million (Q1 2026), -$87.7 million (Q4 2025), and -$33.3 million (Q3 2025), per Business Quant data.